You are here: Industry Insights > Celgene

News List

Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene fiercepharma
May 23, 2018
With Pfizer’s Xeljanz snapping up new indications and AbbVie’s upadacitinib on the way, makers of anti-inflammatory drugs will soon feel the heat from JAK inhibitors if they haven't already. But some will feel it more than others, Bernstein analysts say.
After FDA rebuff, Celgene on track to refile ozanimod—in 2019 fiercebiotech
May 07, 2018
Celgene suffered an embarrassing setback in February when it got a refuse-to-file letter for its multiple sclerosis drug ozanimod. Now, the company says, it expects to resubmit the NDA in the first quarter of 2019, delaying its timeline by a year.
Zymeworks, Celgene expand bispecific antibody partnership biospectrumasia
April 25, 2018
Zymeworks will receive an expansion fee of $164M and will be eligible to receive milestones plus royalties on all products as before.
New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting biospace
April 25, 2018
Celgene Corporation today announced additional phase III data analyses evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator, versus interferon beta-1a
FORMA Meets Objective with Celgene to Advance a Novel Protein Homeostasis Program americanpharmaceuticalreview
April 09, 2018
FORMA Therapeutics has successfully completed a critical objective under its strategic collaboration agreement with Celgene, triggering an undisclosed payment from Celgene
Evaluating Risk: Gilead Sciences, Biogen and Celgene biospace
April 08, 2018
When it comes to large-cap biotech companies, Gilead Sciences, Biogen and Celgene are always worth investment consideration, but are not without their risks.
bluebird backs own CAR-T prospect, takes option to co-develop with Celgene pharmafile
March 30, 2018
Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes.
Celgene and bluebird bio Team Up in New Deal biospace
March 29, 2018
Celgene Corporation and bluebird bio have inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen (BCMA) CAR-T therapy for relapsed/refractory multiple myeloma (rrMM).
Celgene pursues neuro breakthrough with $150m Prosena deal pharmaphorum
March 22, 2018
Celgene is pushing further into the field of neuroscience and dementia research with an alliance with Dublin-based biotech Prosena.
Celgene Partners with Prothena Therapeutics in Potential $2B Deal biospace
March 22, 2018
Shares of Prothena Corporation plc have shot up more than 18 percent in premarket trading this morning

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page